Glaukos reports durable three‑year Epioxa results and announces exclusive retinal‑pipeline licensing deal
Glaukos Corporation released topline data from its GLK‑202‑03 Phase 3 extension study, showing that a single Epioxa treatment sustained a 1.9‑diopter flattening of the cornea and visual‑acuity gains in patients with keratoconus. The trial followed 38 eyes from 35 subjects, with 92 % completing the three‑year follow‑up and no serious adverse events reported. At the same time the company signed an exclusive licensing agreement with RevOpsis Therapeutics to develop the RO‑104 biologic for retinal diseases. Insider selling by the chief development officer accompanied the news, and the stock fell double‑digit on the day.
Why it matters
The company says the data reinforce Epioxa’s long‑term clinical benefit, supporting its commercial rollout and the $680 million‑$700 million 2026 net‑sales guidance. Analyst coverage notes that the licensing deal expands Glaukos’s retinal pipeline, but the share‑price decline reflects investor concern over insider selling and the company’s continued losses.
Key facts
- 1The extension study included 38 eyes from 35 patients. rttnews.com
- 292 % of eyes completed the three‑year follow‑up. rttnews.com
- 3Treated eyes showed a sustained 1.9‑diopter improvement in maximum corneal curvature (Kmax). rttnews.com
- 4At year three, 29 % of eyes gained at least two lines of best‑corrected visual acuity and 20 % gained at least three lines. rttnews.com
- 5Glaukos reported a Q2 2026 net loss of $18.4 million, or $0.31 per diluted share. rttnews.com
- 6Q2 2026 net sales rose 50 % to $185.6 million. rttnews.com
Open questions
- Material 4 reports a 13 % decline while material 6 reports a 10.8 % decline; the exact percentage drop is unclear.
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.